| Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis G Disanto, C Barro, P Benkert, Y Naegelin, S Schädelin, A Giardiello, ... Annals of neurology 81 (6), 857-870, 2017 | 948 | 2017 |
| Defining secondary progressive multiple sclerosis J Lorscheider, K Buzzard, V Jokubaitis, T Spelman, E Havrdova, ... Brain 139 (9), 2395-2405, 2016 | 387 | 2016 |
| Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study P Benkert, S Meier, S Schaedelin, A Manouchehrinia, Ö Yaldizli, ... The Lancet Neurology 21 (3), 246-257, 2022 | 241 | 2022 |
| Predictors of long‐term disability accrual in relapse‐onset multiple sclerosis VG Jokubaitis, T Spelman, T Kalincik, J Lorscheider, E Havrdova, ... Annals of neurology 80 (1), 89-100, 2016 | 204 | 2016 |
| Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis J Kuhle, G Disanto, J Lorscheider, T Stites, Y Chen, F Dahlke, G Francis, ... Neurology 84 (16), 1639-1643, 2015 | 198 | 2015 |
| Association of rituximab treatment with disability progression among patients with secondary progressive multiple sclerosis Y Naegelin, P Naegelin, S von Felten, J Lorscheider, J Sonder, ... JAMA neurology 76 (3), 274-281, 2019 | 73 | 2019 |
| T-cell response against varicella-zoster virus in fingolimod-treated MS patients ME Ricklin, J Lorscheider, A Waschbisch, C Paroz, SK Mehta, DL Pierson, ... Neurology 81 (2), 174-181, 2013 | 72 | 2013 |
| Comparative analysis of natalizumab versus fingolimod as second-line treatment in relapsing–remitting multiple sclerosis J Lorscheider, P Benkert, C Lienert, P Hänni, T Derfuss, J Kuhle, ... Multiple Sclerosis Journal 24 (6), 777-785, 2018 | 54 | 2018 |
| Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis A Cagol, S Schaedelin, M Barakovic, P Benkert, RA Todea, ... JAMA neurology 79 (7), 682-692, 2022 | 51 | 2022 |
| Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS J Lorscheider, VG Jokubaitis, T Spelman, G Izquierdo, A Lugaresi, ... Neurology 89 (10), 1050-1059, 2017 | 46 | 2017 |
| Serum glial fibrillary acidic protein compared with neurofilament light chain as a biomarker for disease progression in multiple sclerosis S Meier, EAJ Willemse, S Schaedelin, J Oechtering, J Lorscheider, ... JAMA neurology 80 (3), 287-297, 2023 | 42 | 2023 |
| The Swiss Multiple Sclerosis Cohort-Study (SMSC): a prospective Swiss wide investigation of key phases in disease evolution and new treatment options G Disanto, P Benkert, J Lorscheider, S Mueller, J Vehoff, C Zecca, ... PloS one 11 (3), e0152347, 2016 | 42 | 2016 |
| A case of progressive multifocal leukoencephalopathy under dimethyl fumarate treatment without severe lymphopenia or immunosenescence M Diebold, V Altersberger, BF Décard, L Kappos, T Derfuss, J Lorscheider Multiple Sclerosis Journal 25 (12), 1682-1685, 2019 | 40 | 2019 |
| Influence of age at disease onset on future relapses and disability progression in patients with multiple sclerosis on immunomodulatory treatment V von Wyl, BF Décard, P Benkert, J Lorscheider, P Hänni, C Lienert, ... European journal of neurology 27 (6), 1066-1075, 2020 | 23 | 2020 |
| Accurate classification of secondary progression in multiple sclerosis using a decision tree R Ramanujam, F Zhu, K Fink, VD Karrenbauer, J Lorscheider, P Benkert, ... Multiple Sclerosis Journal 27 (8), 1240-1249, 2021 | 21 | 2021 |
| Practice effects of mobile tests of cognition, dexterity, and mobility on patients with multiple sclerosis: data analysis of a smartphone-based observational study T Woelfle, S Pless, A Wiencierz, L Kappos, Y Naegelin, J Lorscheider Journal of Medical Internet Research 23 (11), e30394, 2021 | 20 | 2021 |
| Comparative analysis of dimethyl fumarate and fingolimod in relapsing–remitting multiple sclerosis J Lorscheider, P Benkert, C Lienert, P Hänni, T Derfuss, J Kuhle, ... Journal of neurology 268, 941-949, 2021 | 19 | 2021 |
| Anti‐inflammatory disease‐modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study J Lorscheider, J Kuhle, G Izquierdo, A Lugaresi, E Havrdova, D Horakova, ... European journal of neurology 26 (2), 363-370, 2019 | 16 | 2019 |
| Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate V von Wyl, P Benkert, A Moser, J Lorscheider, B Décard, P Hänni, ... Multiple Sclerosis Journal 27 (3), 439-448, 2021 | 15 | 2021 |
| Reliability and acceptance of dreaMS, a software application for people with multiple sclerosis: a feasibility study T Woelfle, S Pless, O Reyes, A Wiencierz, A Feinstein, P Calabrese, ... Journal of Neurology 270 (1), 262-271, 2023 | 14 | 2023 |
